CBLB

CBLB Molekülinformation

Englischer Name	E3 ubiquitin-protein ligase CBL-B	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3	Target-Alias	Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence B，Casitas B-lineage lymphoma proto-oncogene b，RING-type E3 ubiquitin transferase CBL-B，SH3-binding protein CBL-B，RING finger protein 56，Nbla00127，RNF56，Signal transduction protein CBL-B，Cas-Br-M (Murine) Ectropic Retroviral Transforming Sequence B，Cbl Proto-Oncogene， E3 Ubiquitin Protein Ligase B，Cbl Proto-Oncogene B，Cbl Proto-Oncogene B， E3 Ubiquitin Protein Ligase，Cbl-B
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	E3 ubiquitin-protein ligase CBL-B
Target-Alias	Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence B，Casitas B-lineage lymphoma proto-oncogene b，RING-type E3 ubiquitin transferase CBL-B，SH3-binding protein CBL-B，RING finger protein 56，Nbla00127，RNF56，Signal transduction protein CBL-B，Cas-Br-M (Murine) Ectropic Retroviral Transforming Sequence B，Cbl Proto-Oncogene， E3 Ubiquitin Protein Ligase B，Cbl Proto-Oncogene B，Cbl Proto-Oncogene B， E3 Ubiquitin Protein Ligase，Cbl-B
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

CBLB Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
CBB-H5148	Human	E. coli	Human CBLB / RNF56 Protein, His Tag				In den Warenkorb legen

Gesamtmenge1

CBLB Molekülhintergrund

Casitas B-lineage lymphoma proto-oncogene b (CBLB) is also known as RNF56. E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome. Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways. Slightly promotes SRC ubiquitination. May be involved in EGFR ubiquitination and internalization. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. Expressed in placenta, heart, lung, kidney, spleen, ovary and testis, as well as fetal brain and liver and hematopoietic cell lines, but not in adult brain, liver, pancreas, salivary gland, or skeletal muscle.

CBLB Molekülalias

CBL-B,CBLB,RNF56

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
HST-1011	HST-1011; HST1011	Phase 2 Clinical	HotSpot Therapeutics Inc	Neoplasms; Solid tumours	Details
APN-401	APN-401	Phase 1 Clinical	Apeiron Biologics	Brain metastases; Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours	Details
NX-1607	NX-1607	Phase 1 Clinical	Nurix Therapeutics Inc	Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Mesothelioma; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Richter's Syndrome; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms	Details